This is a promotional roadshow of meetings organised and funded by Angelini Pharma UK-I, and is intended for UK healthcare professionals only.
Hear how US and UK experts are using ONTOZRY® for the treatment of drug-resistant focal-onset seizures to help their epilepsy patients reach their goals.
Hear from local experts and Professor Gregory Krauss, Professor of Neurology, Johns Hopkins University School of Medicine, lead author of the pivotal study paper on ONTOZRY®.1
Dr Gregory Krauss focuses on the evaluation and treatment of seizures and epilepsy. He has a particular interest in treating medically resistant epilepsy, evaluating unexplained seizure-like episodes, treating seizures associated with tumour and systemic illnesses and family planning counselling for patients with epilepsy. Dr Krauss also evaluates patients who have failed standard medical therapies for possible treatment with epilepsy surgery, investigational medications or vagal nerve stimulation.
Dr Gregory Krauss received his medical degree from Oregon Health Sciences University. He then completed an internship in medicine at Greenwich Hospital. He went on to complete both a residency in neurology and a fellowship in epilepsy and electrophysiology at the Johns Hopkins Hospital.
Monday 6th June, 18:00 - 20:30
Venue:The Kings Fund, No.11 Cavendish Square, London W1G 0AN
Chair:Professor Ley Sander, Consultant
National Hospital for Neurology and Neurosurgery
Wednesday 8th June, 18:00 - 20:30
Venue:Mourne Seafood Bar, 34-36 Bank Street, Belfast
Chair:Dr Michael Kinney, Consultant Neurologist,
and Social Care Trust
Thursday 9th June, 18:00 - 21:00
Venue:Edgbaston Park Hotel, 53 Edgbaston Park Rd, Birmingham B15 2RS
Chair:Dr Shanika Samarasekera, Consultant
Hospitals Birmingham NHS Foundation Trust
Friday 10th June, 12:30 - 13:30
Venue:John Radcliffe, Oxford OX3 9DU
Chair: Professor Arjune Sen, Consultant
University Hospitals NHS Foundation Trust
To register, select the event you’d like to attend and complete the form with your details.
ONTOZRY® is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products.2
1. Krauss GL, et al. Lancet Neurol. 2020;19(1):38-48
2. ONTOZRY® Summary of Product Characteristics.
UK11637P | April 2022